Skip to content

Monopar Therapeutics MNPR Investment Proceeds

Investment Proceeds at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$88M-35.8%
Prime Medicine logo
Prime MedicinePRME
$50.89M+1,596%
Perspective Therapeutics logo
Perspective TherapeuticsCATX
$47.64M+120%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$67.97M+45.7%
Precigen logo
PrecigenPGEN
$55.1M+1,105%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$126.63M-57.2%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M-62.2%
Net income-$3.9M-48.3%
EPS (diluted)-$0.19

Balance sheet

See full
Cash & equivalents$52.5M+32.3%
Total debt$230.4K+2,692%
Total equity$135.4M+153%
Total assets$138.0M+150%

Cash flow

See full
Operating cash flow-$3.5M+38.7%

Valuation

See full
Market cap$587.04M+192%
Enterprise value$534.72M+232%

Returns & leverage

See full
Return on equity-15.9%-6.6pp
Debt / equity0.0×
Current ratio56×

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monopar Therapeutics's investment proceeds?
Monopar Therapeutics (MNPR) reported investment proceeds of $35.25M in Q1 2026.
How has Monopar Therapeutics's investment proceeds changed year-over-year?
Monopar Therapeutics's investment proceeds increased by 2103.4% year-over-year, from $1.6M to $35.25M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.